Amundi S&P Global Health Care ESG UCITS ETF DR EUR Acc is a equity ETF from Amundi tracking the S&P Global Health Care ESG index through physical replication. Domiciled in Ireland and launched in 2022, the fund manages about 529 M € and charges a TER of 0.18% — 18 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Amundi S&P Global Health Care ESG UCITS ETF DR EUR Acc competes with 261 other products in the same class and region (Equity, Developed markets): it ranks 110th by fund size and 25th by ongoing cost, with a TER of 0.18% against a group median of 0.26%. It has been listed since 2022, 4 years of track record.
On a €10,000 investment the TER costs 18 € a year, against 26 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 54.8% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| Eli Lilly and Company | 12.6% |
| AbbVie Inc | 8.4% |
| UnitedHealth Group Incorporated | 5.2% |
| AstraZeneca PLC | 5.1% |
| Novartis AG | 5.1% |
| Merck & Company Inc | 5.1% |
| Roche Holding AG | 3.9% |
| Amgen Inc | 3.6% |
| Gilead Sciences Inc | 3.1% |
| Intuitive Surgical Inc | 2.7% |
| XETRA | WELS | EUR |
| Euronext Paris | GLHL | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.